3B BlackBio DxBOM:532067 -1.52%63 Interest Coverage is 44.20 as of Mar. 2026, which is 76% below its 10-year median of 181.07. GuruFocus rates BOM:532067 with a GF Score™ of 63/100 and a GF Value™ of ₹2,115.54 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 377 Biotechnology companies, 3B BlackBio Dx ranks better than 53.85% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. 3B BlackBio Dx's
Operating Income
for the
three
months ended in Mar. 2026 was ₹46 Mil. 3B BlackBio Dx's Interest Expense for the
three
months ended in Mar. 2026 was ₹-1 Mil.
3B BlackBio Dx's interest coverage for the quarter that ended in Mar. 2026 was 44.20.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. 3B BlackBio Dx Ltd has enough cash to cover all of its debt. Its financial situation is stable.
The historical rank and industry rank for 3B BlackBio Dx's Interest Coverage or its related term are showing as below:
BOM:532067'
s Interest Coverage Range Over the Past 10 Years
Min: 2.15 Med: 181.07 Max: 654.28
Current: 216.27
BOM:532067's Interest Coverage is ranked better than 53.85% of 377
companies
in the Biotechnology industry
Industry Median: 106.07
vs BOM:532067: 216.27
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
3B BlackBio Dx Interest Coverage Related Terms
3B BlackBio Dx Interest Coverage Historical Data
* Premium members only.
The historical data trend for 3B BlackBio Dx's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
BOM:532067 vs VRTX, REGN, ALNY: Interest Coverage Comparison
For the Biotechnology subindustry, 3B BlackBio Dx's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
3B BlackBio Dx Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, 3B BlackBio Dx's Interest Coverage distribution charts can be found below:
* The bar in red indicates where 3B BlackBio Dx's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
3B BlackBio Dx (BOM:532067) has a Interest Coverage of 44.20 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on 3B BlackBio Dx and its competitors. This is 76% below median its historical median of 181.07. Over the past decade, 3B BlackBio Dx's Interest Coverage has ranged from 2.15 to 654.28. According to the industry distribution chart, 3B BlackBio Dx ranks #174 out of 377 companies in the Biotechnology industry, placing it in the top 46.2%.
Is 3B BlackBio Dx's Interest Coverage too high?
3B BlackBio Dx's current Interest Coverage of 44.20 is 76% below median its 10-year median of 181.07. Over the past 10 years, this metric has ranged from a low of 2.15 to a high of 654.28. The Biotechnology industry median Interest Coverage is 106.07. 3B BlackBio Dx's value of 44.20 is 58.3% below this industry median. Based on the distribution chart, 3B BlackBio Dx ranks #174 out of 377 companies in the Biotechnology industry, which is above the industry midpoint. Overall, 3B BlackBio Dx has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does 3B BlackBio Dx's Interest Coverage compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, 3B BlackBio Dx ranks #174 out of 377 companies for Interest Coverage. This puts 3B BlackBio Dx in the upper half of its industry. The industry median Interest Coverage is 106.07. 3B BlackBio Dx's value of 44.20 is 58.3% below this benchmark. Historically, 3B BlackBio Dx's own Interest Coverage has ranged from 2.15 to 654.28 over the past decade. While the company's 10-year median is 181.07 vs. the industry median of 106.07, 3B BlackBio Dx has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 106.07, based on 377 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. 3B BlackBio Dx's current Interest Coverage of 44.20 is 58.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on 3B BlackBio Dx and its competitors. For the Biotechnology industry, the median Interest Coverage is 106.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 3B BlackBio Dx's current Interest Coverage is 44.20, which is 76% below median its own 10-year median of 181.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 3B BlackBio Dx stock overvalued right now?
Based on GuruFocus' analysis, 3B BlackBio Dx (BOM:532067) is currently considered Possible Value Trap. The stock's GF Value™ is ₹2,115.54, compared to a current price of ₹1,153.30 — trading 45.5% below its estimated fair value. The current Interest Coverage is 44.20, which is 76% below median its 10-year median of 181.07 and 58.3% below the Biotechnology industry median of 106.07. 3B BlackBio Dx's overall GF Score™ is 63/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For 3B BlackBio Dx (BOM:532067), the current Interest Coverage is 44.20 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 3B BlackBio Dx (BOM:532067) Overvalued in 2026?
Based on GuruFocus' analysis, 3B BlackBio Dx stock appears to be undervalued.
The current stock price of ₹1,153.30 is trading 45.5% below its estimated GF Value™ of ₹2,115.54.
GuruFocus considers 3B BlackBio Dx to be Possible Value Trap.
Key valuation signals for BOM:532067:
Interest Coverage: 44.20 (76% below median its 10-year median of 181.07)
GF Value™: ₹2,115.54 vs. price of ₹1,153.30 (45.5% below fair value)
Industry Position: 58.3% below the Biotechnology median (#174 of 377)
No single metric tells the full story. See the BOM:532067 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
3B BlackBio Dx Ltd is an Indian company specializing in PCR-based Molecular Diagnostic Kits. The company is involved in designing, developing, manufacturing, and commercializing PCR-based Molecular Diagnostic kits, PCR Enzymes, and PCR Reagents.
63GF Score
Get the complete analysis for BOM:532067
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:532067 has been successfully added to your 
